Response to: Comment on l'Ami et al titled 'Successful reduction of overexposure in patients with rheumatoid arthritis with high serum adalimumab concentrations: an open-label, non-inferiority, randomised clinical trial' by den Broeder et al. Issue 10 (13th November 2017) - l'Ami, Merel J; Krieckaert, Charlotte L M; Nurmohamed, Michael T; van Vollenhoven, Ronald F; Rispens, Theo; Boers, Maarten; Wolbink, Gerrit Jan